S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
pixel
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
pixel
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
pixel
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
pixel
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
NASDAQ:CRSP

CRISPR Therapeutics - CRSP Stock Forecast, Price & News

$81.40
+2.49 (+3.16%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$75.14
$81.90
50-Day Range
$55.27
$83.78
52-Week Range
$42.51
$142.64
Volume
1.64 million shs
Average Volume
1.59 million shs
Market Capitalization
$6.31 billion
P/E Ratio
22.55
Dividend Yield
N/A
Price Target
$113.27

CRISPR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
39.1% Upside
$113.27 Price Target
Short Interest
Bearish
16.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of CRISPR Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$3.44 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.98) to ($7.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

140th out of 1,283 stocks

Biological Products, Except Diagnostic Industry

20th out of 197 stocks

CRSP stock logo

About CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Needham & Company LLC reduced their target price on CRISPR Therapeutics from $170.00 to $122.00 in a report on Friday, May 13th. BMO Capital Markets began coverage on CRISPR Therapeutics in a research note on Thursday, June 16th. They set an "outperform" rating and a $98.00 price target for the company. Piper Sandler lifted their price target on CRISPR Therapeutics from $115.00 to $121.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 22nd. Royal Bank of Canada dropped their price objective on CRISPR Therapeutics from $95.00 to $85.00 in a research report on Tuesday, May 10th. Finally, The Goldman Sachs Group dropped their price objective on CRISPR Therapeutics from $52.00 to $46.00 and set a "neutral" rating for the company in a research report on Tuesday, May 24th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $116.19.

CRISPR Therapeutics Stock Up 3.2 %

Shares of CRISPR Therapeutics stock opened at $81.40 on Friday. The business has a fifty day simple moving average of $70.64 and a 200 day simple moving average of $63.09. The stock has a market cap of $6.31 billion, a PE ratio of 22.55 and a beta of 1.93. CRISPR Therapeutics has a 12 month low of $42.51 and a 12 month high of $142.64.

CRISPR Therapeutics (NASDAQ:CRSP - Get Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($2.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.91) by ($0.41). CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. The business had revenue of $0.94 million for the quarter, compared to analyst estimates of $2.45 million. During the same period last year, the firm earned ($1.51) EPS. CRISPR Therapeutics's quarterly revenue was up 74.4% compared to the same quarter last year. Analysts expect that CRISPR Therapeutics will post -8.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $75.91, for a total value of $1,897,750.00. Following the completion of the transaction, the chief executive officer now directly owns 290,279 shares in the company, valued at approximately $22,035,078.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.70% of the company's stock.

Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Stock News Headlines

MarketBeat: Week in Review 8/1 - 8/5 (CRSP)
The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow.
Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment
Cathie Wood Dumped These 7 Stocks in July
Will CRISPR Stock Double in the Next Year?
Why CRISPR Therapeutics Stock Is Falling
Crispr stock drops over 10% on Innovation Day
See More Headlines
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Company Calendar

Last Earnings
5/09/2022
Today
8/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
Fax
N/A
Employees
473
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$113.27
High Stock Price Forecast
$220.00
Low Stock Price Forecast
$46.00
Forecasted Upside/Downside
+39.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
16 Analysts

Profitability

Net Income
$377.66 million
Pretax Margin
34.58%

Debt

Sales & Book Value

Annual Sales
$914.96 million
Cash Flow
$5.36 per share
Book Value
$31.35 per share

Miscellaneous

Free Float
69,169,000
Market Cap
$6.31 billion
Optionable
Optionable
Beta
1.93














CRSP Stock - Frequently Asked Questions

Should I buy or sell CRISPR Therapeutics stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics
or view top-rated stocks.

What is CRISPR Therapeutics' stock price forecast for 2022?

16 Wall Street research analysts have issued 1-year price targets for CRISPR Therapeutics' stock. Their CRSP stock forecasts range from $46.00 to $220.00. On average, they anticipate CRISPR Therapeutics' share price to reach $113.27 in the next twelve months. This suggests a possible upside of 39.1% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics
or view top-rated stocks among Wall Street analysts.

How has CRISPR Therapeutics' stock price performed in 2022?

CRISPR Therapeutics' stock was trading at $75.78 at the beginning of 2022. Since then, CRSP stock has increased by 7.4% and is now trading at $81.40.
View the best growth stocks for 2022 here
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) released its quarterly earnings results on Monday, May, 9th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($1.91) by $0.41. The business earned $0.94 million during the quarter, compared to the consensus estimate of $2.45 million. CRISPR Therapeutics had a net margin of 34.04% and a trailing twelve-month return on equity of 12.77%. The company's revenue for the quarter was up 74.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.51) earnings per share.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (5.92%), Nikko Asset Management Americas Inc. (5.92%), Loomis Sayles & Co. L P (1.80%), Allspring Global Investments Holdings LLC (0.35%), Green Alpha Advisors LLC (0.29%) and Frontier Capital Management Co. LLC (0.22%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics
.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $81.40.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $6.31 billion and generates $914.96 million in revenue each year. The company earns $377.66 million in net income (profit) each year or $3.61 on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 473 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for CRISPR Therapeutics is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.

This page (NASDAQ:CRSP) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.